A Two-Part, Single-Dose Study of the Pharmacokinetics of MK-8931 in Subjects With Renal Insufficiency (MK-8931-009 [P08535])

NCT ID: NCT01537757

Last Updated: 2015-01-26

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 12 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2012-03-31
• Study Completion Date: 2012-05-31

Brief Summary

This study will assess the pharmacokinetics of MK-8931, a ß-secretase inhibitor, in participants with renal insufficiency. In Part 1 of the study, pharmacokinetics of MK-8931 in participants with severe renal disease and in healthy matched control participants will be studied. If data from Part 1 confirms that severe renal impairment does not alter the pharmacokinetics of MK-8931 to the extent requiring dosage adjustment, then no further study will be required and Part 2 will be optional. If the data does not support this conclusion, then Part 2 will be conducted to study the pharmacokinetics of MK-8931 in participants with moderate and mild renal impairment compared to healthy matched controls.

Conditions

Alzheimer's Disease

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Part 1, Panel A - Severe Renal Impairment Group

Group Type: EXPERIMENTAL

MK-8931

Intervention Type: DRUG

Single dose, administered as oral capsules

Part 1, Panel B - Healthy Control Group to Match Panel A

Group Type: EXPERIMENTAL

MK-8931

Intervention Type: DRUG

Single dose, administered as oral capsules

Part 2, Panel C - Moderate Renal Impairment Group

Group Type: EXPERIMENTAL

MK-8931

Intervention Type: DRUG

Single dose, administered as oral capsules

Part 2, Panel D - Healthy Control Group to Match Panel C

Group Type: EXPERIMENTAL

MK-8931

Intervention Type: DRUG

Single dose, administered as oral capsules

Part 2, Panel E - Mild Renal Impairment Group

Group Type: EXPERIMENTAL

MK-8931

Intervention Type: DRUG

Single dose, administered as oral capsules

Part 2, Panel F - Healthy Control Group to Match Panel E

Group Type: EXPERIMENTAL

MK-8931

Intervention Type: DRUG

Single dose, administered as oral capsules

Interventions

MK-8931

Single dose, administered as oral capsules

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Body Mass Index ≤39 kg/m^2
• No clinically significant abnormality on electrocardiogram
• Female participant must be postmenopausal or surgically sterilized
• Non-vasectomized men must agree to use a condom with spermicide or abstain from sexual intercourse, during the trial and for 3 months after stopping the medication

• Clinical diagnosis of renal insufficiency based on Estimated Glomerular Filtration rate (eGFR): severely decreased eGFR, defined as <30 mL/min/1.73m^2 and participant is not on dialysis; moderately decreased eGFR, defined as ≥30 to <60 mL/min/1.73m^2; mildly decreased eGFR, defined as ≥60 to <80 mL/min/1.73m^2
• Stable baseline health based on medical history, physical examination, vital signs, and laboratory tests

Inclusion Criterion Specific to Healthy Participants:

• eGFR ≥80 mL/min/1.73m^2

Exclusion Criteria

• Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of any drug, including history or presence of inflammatory bowel disease, gastrointestinal or rectal bleeding; presence of active ulcer; history of major gastrointestinal tract surgery such as gastrectomy, gastroenterostomy, or bowel resection; history of pancreatic injury or pancreatitis; history or presence of liver disease or liver injury; history of urinary obstruction or difficulty in voiding
• History of any infectious disease within 4 weeks prior to drug administration
• Positive for hepatitis B surface antigen (HBsAg), hepatitis C antibodies (HCV) or human immunodeficiency virus (HIV)
• History of risk factors for Torsades de Pointes (e.g., heart failure/cardiomyopathy or family history of Long QT Syndrome)
• Participant has had a kidney removed or has a functioning renal transplant
• History of alcohol or drug abuse in the past 2 years
• Blood donation or loss of significant volume of blood in the past 60 days prior to dosing
• Previously received MK-8931
• History of significant multiple and/or severe allergies (including latex allergy), or anaphylactic reaction or significant intolerability to prescription or non-prescription drugs or food
• History of malignancy occurring within the 5 years immediately before screening, except for a participant who has been adequately treated for basal cell or squamous cell skin cancer; or in situ cervical cancer; or

localized prostate carcinoma; or has undergone potentially curative therapy with no evidence of recurrence ≥1 year post-therapy

• Rapidly fluctuating renal function as determined by historical measurements
• Suspected renal artery stenosis

• Minimum Eligible Age: 50 Years
• Maximum Eligible Age: 85 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Merck Sharp & Dohme LLC

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Other Identifiers

MK-8931-009

Identifier Type: OTHER

Identifier Source: secondary_id

P08535

Identifier Type: -

Identifier Source: org_study_id